We are a CNS-focused company providing drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models. Our capabilities include dose-response studies, pharmacodynamics, model phenotyping and phenotypic screening for lead selection and validation in Epilepsy, Movement disorders and cognitive disorders.
Hugo Monchal
[email protected]
Saint-Ismier, France
0750144695
https://synapcell.com
Our Representatives
Since 2005, SynapCell has built its reputation as a leader in predictive efficacy testing in the field of CNS disorders, supporting international biopharmaceutical companies in identifying their most promising drug candidates and securing their preclinical to clinical roadmap.
Driven by a constantly growing innovation pipeline, we have been developing and expanding the applications of Cue®, our proprietary technology platform towards therapeutic areas and strategies with high unmet needs.
We discovered translational, robust, and objective EEG biomarkers in clinically relevant animal models in vivo following intensive R&D efforts. They are routinely being used to unlock the true pharmacodynamic potential of neurotherapeutics that target epileptic, motor (Essential Tremor, Parkinson’s disease, LID), cognitive disorders or rare diseases affecting the brain.
Our expert scientists are used to work with any typology of biopharmaceutical companies that range from small ventures to large pharma. What's important for them is the extra mile we are delivering across our expertise, our ability to adapt to their timelines and scientific constraints, as well as the excellent quality of work form study design to final report.
Daily interactions with our experts allow for making the most out of a project at every step and our commitment for delivering clear, comprehensive, and documented information help our clients status on a GO/NO GO decision for the next step of their drug development.